NANTES, France--(BUSINESS WIRE)--Regulatory News:
OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE), today announced the appointment of Dr. Frédérique Corallo to the position of Chief Medical Officer, Immunology, further strengthening the Company’s scientific and medical expertise within this therapeutic area.
Dr. Corallo will lead the development of OSE Immunotherapeutics’s innovative products, with a particular emphasis on autoimmune diseases.
Dr. Corallo is a physician, specializing in immunology, and has over 25
years of global experience in the pharmaceutical and biotechnology
industries. Prior to joining OSE Immunotherapeutics, she spent over 10
years as Medical Director at Biogen, one of the world leading
biotechnology companies.
Dr. Corallo previously held management
positions in Medical Affairs and Clinical Research at multiple
biopharmaceutical companies, including Janssen Cilag and Sanofi (Hoechst
Marion Roussel). Throughout her career, she has led strategic and
operational management of immunology-related clinical development
programs and medical marketing activities.
"Frédérique’s expertise in the area of immunology, and her vast experience overseeing drug development programs and medical affairs initiatives, will be critical to further advancing our immunotherapy products and strengthening OSE immunotherapeutics’s competitive position in this field", commented Dominique Costantini, CEO of OSE Immunotherapeutics.
ABOUT OSE IMMUNOTHERAPEUTICS
Our ambition is to become
a world leader in activation and regulation immunotherapies
OSE
Immunotherapeutics is a biotechnology company led by world-class
immunologists and focused on the development of innovative
immunotherapies for immune activation and regulation in the fields of
immuno-oncology, auto-immune diseases and transplantation.
The company has a balanced portfolio of first-in-class products with a diversified risk profile ranging from clinical phase 3 registration trials to R&D:
- Tedopi®, a combination of 10 optimized neo-epitopes to induce specific T activation in immuno-oncology - currently in registration Phase 3 trial advanced NSCLC HLA A2+ patients EU /US - Orphan Status in the US - registration expected in 2019 - a Phase 2 with Tedopi® in combination with a checkpoint inhibitor in NSCLC is considered in 2017 - the product is also considered in other cancer indications.
- FR104, CD28-antagonist in immunotherapy - Phase 1 trial completed – for the treatment of autoimmune diseases and for use with transplantation - licensed to Janssen Biotech Inc. to pursue clinical development
- Effi-7, interleukin receptor-7 antagonist - in preclinical development for inflammatory bowel diseases and other autoimmune diseases
- Effi-DEM, new generation checkpoint inhibitor targeting the SIRP-α receptor - in preclinical development for immuno-oncology
- R&D: candidates targeting new receptors in immuno-oncology
The portfolio’s blockbuster potential gives OSE Immunotherapeutics the ability to enter global agreements at different stages of development with major pharmaceutical players.
Immunotherapy is a highly promising and growing market. By 2023 Immunotherapy of cancer could represent nearly 60% of treatments against less than 3% at present * and the projected market is estimated at $67 billion in 2018 **.
There are more than 80 autoimmune diseases that represent a significant market including major players in the pharmaceutical industry with sales towards $10 billion for the main products. The medical need is largely unmet and requires the provision of new innovative products involved in the regulation of the immune system.
*Citi Research Equity
**BCC Research
More information: http://ose-immuno.com
Click and follow us on Twitter and Linkedln
Forward-looking statements
This press release
contains express or implied information and statements that might be
deemed forward-looking information and statements in respect of OSE
Immunotherapeutics. They do not constitute historical facts. These
information and statements include financial projections that are based
upon certain assumptions and assessments made by OSE Immunotherapeutics’
management in light of its experience and its perception of historical
trends, current economic and industry conditions, expected future
developments and other factors they believe to be appropriate.
These
forward-looking statements include statements typically using
conditional and containing verbs such as “expect”, “anticipate”,
“believe”, “target”, “plan”, or “estimate”, their declensions and
conjugations and words of similar import.
Although the OSE
Immunotherapeutics management believes that the forward-looking
statements and information are reasonable, the OSE Immunotherapeutics’
shareholders and other investors are cautioned that the completion of
such expectations is by nature subject to various risks, known or not,
and uncertainties which are difficult to predict and generally beyond
the control of OSE Immunotherapeutics. These risks could cause actual
results and developments to differ materially from those expressed in or
implied or projected by the forward-looking statements. These risks
include those discussed or identified in the public filings made by OSE
Immunotherapeutics with the AMF. Such forward-looking statements are not
guarantees of future performance.
This press release includes only
summary information and should be read with the OSE Immunotherapeutics
Reference Document filed with the AMF on 8 June 2016 under the number
R.16-052, the consolidated financial statements and the management
report for the fiscal year 2015, as well as the Merger Document
registered with the AMF on 26 April 2016 under number E.16-026, all
available on the OSE Immunotherapeutics’ website.
Other than as
required by applicable law, OSE Immunotherapeutics issues this press
release at the date hereof and does not undertake any obligation to
update or revise the forward-looking information or statements.
